Pulmatrix reports FY2022 revenue $6.1M, net loss $18.8M; cash $35.6M into Q2 2024

Pulmatrix, Inc.

Revenue $6.1M (+$0.9M YoY); net loss $18.8M vs $20.2M; EPS -$5.46 vs -$8.63.
Cash $35.6M at Dec 31, 2022; runway into Q2 2024.
PUR1900 Phase 2b in ABPA dosed first patients in Q1 2023; topline data expected mid-2024.
PUR3100 Phase 1 for acute migraine positive: lower nausea vs IV DHE; plans for Phase 2.
PUR1800 Phase 1b data presented; analysis ongoing for potential Phase 2 study.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pulmatrix, Inc. reported the year ended December 31, 2022 results: revenue $6.1 million.

Period: the year ended December 31, 2022
Revenue: $6.1 million
Result: reported results

Exact text from the filing

Revenue was $6.1 million for the year ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

Pulmatrix, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-009607

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.